AbstractObjectivesDiabetes mellitus intensify the risks and complications related to COVID-19 infection. A major effect of the pandemic has been a drastic reduction of in-person visits. The aim of this study was to evaluate the impact of the COVID-19 pandemic on HbA1cmanagement and results among pediatric and adult outpatients with diabetes, considering the laboratory and point-of-care testing (POCT) HbA1cmeasurements.MethodsObservational retrospective study including patients from pediatric and adult diabetes units was conducted. HbA1cresults obtained in the laboratory and POCT over 3 years (2019–2021) were collected from the laboratory information system.ResultsAfter the lockdown, the number of HbA1cplummeted. Children returned soon to routine clinical practice. The number of HbA1cincreased gradually in adults, especially in POCT. Globally, HbA1cresults were lower in children compared with adults (p<0.001). HbA1cvalues in children (p<0.001) and adults (p=0.002) decreased between pre-pandemic and post-pandemic periods, though lower than the HbA1creference change value. The percentage of HbA1cresults above 8% remained stable during the study period.ConclusionsContinuous glucose monitoring and a telemedicine have been crucial, even allowing for improvements in HbA1cresults. During the lockdown, patients with better metabolic control were managed in the laboratory whereas patients with poorer control or a severe clinical situation were attended in diabetes units by POCT. Adults returned to pre-pandemic management slowly because they were more susceptible to morbidity and mortality due to COVID-19. Coordination among all health professionals has been essential to offering the best management, especially in difficult scenarios such as the COVID-19 pandemic.